Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SOS2 | Q07890 | 1/20 | 0.58 |
| ▸ | MAPT | P10636 | 4/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.52 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.52 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.51 |
| ▸ | HTR2A | P28223 | 1/20 | 0.50 |
| ▸ | ITGB2 | P05107 | 2/20 | 0.48 |
| ▸ | ICAM1 | P05362 | 2/20 | 0.48 |
| ▸ | ITGAL | P20701 | 2/20 | 0.48 |
| ▸ | BRPF1 | P55201 | 1/20 | 0.48 |
| ▸ | NR3C1 | P04150 | 2/20 | 0.47 |
| ▸ | PPARG | P37231 | 1/20 | 0.45 |
| ▸ | PPARA | Q07869 | 1/20 | 0.45 |
| ▸ | PGR | P06401 | 1/20 | 0.45 |
| ▸ | NR3C2 | P08235 | 1/20 | 0.45 |
| ▸ | POLB | P06746 | 3/20 | 0.44 |
| ▸ | TP53 | P04637 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | APAF1 | O14727 | 1/20 | 0.44 |
| ▸ | RECQL | P46063 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24328897 | 0.86 | MTNR1A (0.58) | SOS2MAPTSMN1; SMN2HTR2APOLB | |
| SCHEMBL24301112 | 0.85 | GPR84 (0.54) | MAPTHTR2AITGB2ICAM1ITGAL | |
| SCHEMBL24328907 | 0.85 | NR4A2 (0.52) | MAPTSMN1; SMN2NR4A2HTR2AITGB2 | |
| SCHEMBL12039401 | 0.83 | SOS2 (0.65) | SOS2MAPTSMN1; SMN2NPSR1NR4A2 | |
| SCHEMBL25842242 | 0.83 | SOS2 (0.65) | SOS2MAPTSMN1; SMN2NPSR1NR4A2 | |
| SCHEMBL28417401 | 0.83 | SMN1; SMN2 (0.61) | SOS2MAPTSMN1; SMN2NPSR1NR4A2 | |
| SCHEMBL24328921 | 0.83 | SMN1; SMN2 (0.61) | SOS2MAPTSMN1; SMN2NPSR1NR4A2 | |
| SCHEMBL24328906 | 0.83 | HTR6 (0.42) | SOS2MAPTSMN1; SMN2HTR2APOLB | |
| SCHEMBL10023253 | 0.82 | SOS2 (0.68) | SOS2MAPTSMN1; SMN2NPSR1NR4A2 | |
| SCHEMBL2033277 | 0.82 | SOS2 (0.68) | SOS2MAPTSMN1; SMN2NPSR1NR4A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230399297-A1 | Novel Glutamine Analogs | JACOBIO PHARMACEUTICALS CO., LTD (CN) | 2023-12-14 | — | — | US | disclosed |
| US-20230399297-A1 | Novel Glutamine Analogs | JACOBIO PHARMACEUTICALS CO., LTD (CN) | 2023-12-14 | — | — | US | disclosed |
| WO-2022078416-A1 | NOVEL GLUTAMINE ANALOGS | JACOBIO PHARMACEUTICALS CO., LTD. (CN) | 2022-04-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230399297-A1 | Novel Glutamine Analogs | GLUL, GATD3, GLS | SOS2 4511/4885MAPT 2809/4885SMN1; SMN2 3812/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.